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Head and neck cancer
Head and neck cancer is the eight most common cancer in the world with an 
estimated incidence of 890,000 cases per year in 20171. It commonly refers to a 
collection of cancers, predominantly squamous cell carcinomas (HNSCC) arising 
from the epithelial lining of the oral cavity, pharynx and larynx. This thesis focuses 
on HNSCC and in particular laryngeal squamous cell carcinomas (LSCC).
Laryngeal squamous cell carcinoma
Of all HNSCC, 25% originate in de larynx. In recent years, around 700 cases of LSCC 
were diagnosed annually in the Netherlands2. Smoking and alcohol consumption 
are the major risk factors for developing LSCC. Unlike in oropharynx carcinoma, in 
LSCC high-risk HPV16 or HPV18 infections are rarely seen as a risk factor. Low-risk 
HPV6 and HPV11 are strongly associated with recurrent respiratory papillomatosis 
in the larynx but not detected in LSCC3. 
Treatment options of LSCC consist of surgery (endoscopic or external approach), 
radiotherapy, and a combination of these treatments or chemoradiation4. Based on 
national and international guidelines, in our institute early stage LSCC patients are 
treated with radiotherapy as single modality treatment with the exception of T
1a
 
glottic LSCC in which transoral CO
2
 laser microscopic surgery can be an alternative 
with equivalent results compared to radiotherapy5-7. Although a meta-analysis 
revealed that there was insufficient evidence to establish a clear superiority for 






 glottic cancer8, laser surgery has 
the advantage of keeping all treatment modalities available for the treatment of 




) LSCC, hyperfractionated or 
accelerated radiotherapy is the treatment of choice to preserve laryngeal function 




) disease is treated with 
radiotherapy or combined chemoradiation, unless no functional larynx is present 
or can be expected after treatment. In these cases, total laryngectomy needs to 
be considered. In case chemoradiation is not feasible for patients with locally 
advanced non-metastatic LSCC, the use of EGFR-targeted therapy (e.g. cetuximab) 
is approved by the U.S. Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) in combination with radiotherapy based on studies 
by Bonner et al.9-11. However, specifically in laryngeal cancer adding cetuximab 
to the radiation therapy does not seem to improve survival12. Patients with a 
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positive lymph node status (N+) require definitive treatment of the neck, either by 
comprehensive neck dissection or by definitive (chemo)radiation. For supraglottic 
LSCC, elective bilateral treatment of the neck should be undertaken for T
2
 or higher 
stages. However, for patients with glottic disease sole treatment of the primary 
site is sufficient and elective unilateral treatment of the neck is not needed until 
tumors are stages T
3
 or greater4.
Radiotherapy for the treatment of laryngeal cancer 
Radiotherapy plays an important role in the treatment of LSCC patients. Efficacy of 
radiotherapy relies on DNA damage, either via direct damage of DNA by ionizing 
radiation or by free radicals that are generated and subsequently react with DNA, 
which is the more common mechanism of DNA damage. This leads to single and 
double strand DNA breaks, which ultimately result in apoptosis13. An increasing 
radiotherapy dose will lead to increasing cell death of neoplastic cells. However, 
normal cells will also be damaged which leads to toxic side effects like dermatitis, 
mucositis, pain, dysphagia and xerostomia. To prevent these side effects, patients 
are treated with fractionated radiotherapy to enable normal tissues to recover and 
repopulate. However, recovery and repopulation does not only occur in normal 
tissue, but also in neoplastic cells. To reduce repopulation of neoplastic cells, 
accelerated radiotherapy is given with a daily dose of 2 Gy for six fractions per 
week for a total of 66-70 Gy in total.
The local control rate for T1-T2 laryngeal carcinoma obtained with primary 
radiotherapy is 70-95%14-16. In case of local recurrence, frequently a disabling 
total laryngectomy is required as a salvage surgery. Moreover, complications and 
morbidity are considerably high in patients who undergo a salvage laryngectomy 
after radiotherapy with/without chemotherapy17.
Prognostic tumor-specific biomarkers for LSCC treated with radiotherapy




) LSCC treated with radiotherapy will result in a 
disabling total laryngectomy. Given the high recurrence rate, prognostic factors 
for the development of a local recurrence after primary radiotherapy are needed 
to select the most optimal treatment for individual patients. Besides TNM 
classification, anterior commissure involvement, sublocation in which supraglottic 
cancers have worse prognosis than glottic cancers and a number of clinical factors, 
like smoking and alcohol consumption habits, there is a lack of clinical prognostic 
factors to predict worse local control after radiotherapy in LSCC4,18,19. 




In the past decades, research has concentrated on the identification of new 
tumor specific biomarkers to predict clinical outcome. Especially markers involved 
in tumorigenesis and tumor progression, such as genes associated with processes 
like apoptosis, angiogenesis and cell growth, have been investigated extensively 
in relation with radioresponse in LSCC13,19,20. 
Hypoxia as a prognostic factor 
Among the several mechanisms proposed as potential causes of radioresistance, 
hypoxia has been studied the most21. Hypoxia is characteristic for many solid 
tumors, including head and neck cancer21-23. It was already proposed in the 1950s 
that the radiosensitivity of tumors is limited by hypoxia24. The biological effect of 
radiotherapy depends on the degree of tissue oxygenation and hypoxic cells are 
approximately threefold more resistant to radiation than well oxygenated cells25-28. 
Oxygen free radicals are highly reactive and are the primary source of radiation-
induced DNA damage. Therefore, oxygen is a potent radiosensitizer. Indirectly, 
hypoxia-induced genomic changes may have impact on radiation resistance 
by altering proliferation, cell cycle, apoptosis, angiogenesis and anaerobic 
glycolysis29-31. In many tumor types, including head and neck cancer, hypoxia is 
associated with worse locoregional control22,23,27,31,32. 
Patients with a hypoxic tumor might benefit from hypoxic modification 
during radiotherapy treatment. For example application of hypoxia sensitizers as 
nitroimidazoles to radiotherapy, radiotherapy with carbogen and nicotinamide 
(ARCON) or increased radiation dose to hypoxic areas or hyperbaric oxygen 
treatment have been investigated in HNSCC26,33-35. 
However, assessing tumor hypoxia is a challenge. Direct measurement 
of tumor oxygenation is possible with (Eppendorf) polarographic needle 
electrodes31,36,37. Clinical studies demonstrated that this method could be used to 
predict tumor response and treatment outcome in patients with HNSCC treated 
with radiotherapy38. However, a later study by the same researchers disagreed 
with the conclusions in their first study39. This can partly be explained by the 
spatial heterogeneity of hypoxia in the tumor. An important disadvantage of using 
the needle electrodes is the restricted use to accessible tumors and intertumoral 
heterogeneity of hypoxia known for many years40.
Other, histological, methods to asses tumor hypoxia are the use of exogenous 
(2-nitroimidazole compounds such as pimonidazole) and endogenous (HIF1α, CA-
IX, GLUT-1) hypoxia markers using immunohistochemistry28,31,41. The advantage is 
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that presence of hypoxia could be related to histological morphology.  Exogenous 
markers are drugs, chemicals or even bacteria that, after administration to the 
patient, specifically accumulate or are bio-reducible under hypoxic conditions. 
Binding is ascertained in tissue biopsies using specific antibodies. One of the 
clinically relevant markers is the 2-nitroimidazole pimonidazole42,43 that is injected 
intravenously before biopsy taken or surgery. It is reductively activated and forms 
protein products in mammalian cells at low pO
2
 level43. The prognostic significance 
of pimonidazole was demonstrated by Kaanders et al. who showed worse 
locoregional control in patients with high pimonidazole binding as compared to 
low pimonidazole binding in advanced head and neck cancer44. The disadvantage 
of exogenous markers is that the chemical solution must be administered 
intravenously to the patient before biopsy/surgery. Therefore, expression of 
exogenous hypoxia markers can only be investigated in tissue samples from 
patients who underwent this procedure preoperative and was performed only in 
few retrospective studies.
Under hypoxic conditions, hypoxia inducible factor 1-alpha (HIF1α) is 
upregulated, which leads to activation of transcription of many genes, including 
carbonic anhydrases and glucose transporters. These proteins are involved in many 
processes, such as angiogenesis, pH-regulation, cell proliferation, cell survival 
and apoptosis, erythropoiesis, and energy and glucose metabolism45,46. Increased 
expression of HIF1α detected by immunohistochemistry has been associated with 
poor locoregional control after radiotherapy in LSCC32,47,48. Carbonic anhydrase IX 
(CA-IX) catalyzes reversible hydration of carbon dioxide to carbonic acid thereby 
maintaining a stable intracellular pH in hypoxic conditions. High expression of 
CA-IX was found in many different tumor tissues. In vitro and in vivo studies 
demonstrated that CA-IX was strongly induced by hypoxia in a broad range of 
tumors. It was also shown that CA-IX positivity was associated with resistance to 
radiation32,49,50. In contrast, low expression of CA-IX was predictive for response 
to accelerated radiotherapy with carbogen breathing and nicotinamide (ARCON), 
a hypoxia target therapy, in laryngeal cancer51. Although CA-IX is a promising 
hypoxia marker, a weak correlation with pimonidazole44 questioned its value as 
a marker for hypoxia. However, we cannot exclude that pimonidazole is poorly 
associated with hypoxia and thus CA-IX is a good predictor because studies are 
lacking to correlate expression with hypoxic tumor areas. GLUT-1 appeared to be 
one of the prominent glucose transporters. Increased expression enables higher 
cellular uptake of glucose and facilitates anaerobic glycolysis52. GLUT-1 expression 




in head and neck tumors is found at distance from vessels and adjacent to necrotic 
areas, and indicates diffusion-limited hypoxia53. Furthermore, a correlation with 
oxygen electrode measurements and expression of pimonidazole and CA-IX was 
found54,55.
In summary, HIF1α, CA-IX and GLUT-1 are the most extensively studied 
endogenous markers of tumor hypoxia. These biomarkers were associated with 
worse survival and local control, almost regardless of the therapy provided. 
Differences in outcome between various studies can be explained by spatial 
heterogeneity in the distribution of hypoxia, many ways to score biomarker 
expression levels and the use of different cutoff levels to define low/high expression 
reported in literature. In addition, expression of many hypoxia-related genes may 
be a complex function of hypoxia-dependent and -independent pathways 52. For 
instance, HIF1α, CA-IX and GLUT-1 accumulation can be observed also under other 
conditions than hypoxia, for example, hypoglycemia and acidosis56 suggesting 
these markers are not robust hypoxia markers but might reflect a more aggressive 
tumor phenotype57.
Hypoxia imaging
Alternative and non-invasive methods to obtain information about the 
oxygenation status with the possibility to use this for radiotherapy treatment 
planning (for escalating the dose to the hypoxic regions) include the use of 
radiologic and nuclear imaging techniques. During the past decades many PET 
tracers for detecting the proportion of hypoxic cells in vivo have been developed. 
Most widely used are the 2-nitroimidazoles like 18F-labeled fluoromisonidazole 
(18F-FMISO) or 18F-fluoroazomycinarabinoside (18F-FAZA)-PET58. Several animal and 
human studies evaluated the use of radiolabeled nitroimidazoles for assessment 
of the oxygenation status in solid tumors59,60. Clinical studies performed on 
patients with head and neck cancer demonstrated the potential prognostic value 
of hypoxia imaging with 18F-FMISO for radiotherapy outcome61-64. In a small group 
of patients with HNSCC, pre-treatment tumor hypoxic fraction assessed using PET 
imaging of 18F-FAZA was predictive of survival following radiotherapy65. However, 
the ideal hypoxia PET tracer should express only relevant oxygen concentrations 
in viable cells and possess uniform and rapid cell entry (lipophilic molecule), 
rapid clearance from normoxic cells (hydrophilic molecule) and yielding a high 
target-to-background ratio. Overall, fluorinated nitroimidazoles have a low tumor 
uptake relative to surrounding tissue and 18F-FAZA has been shown to be superior 
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to 18F-FMISO66,67. None of the radiotracers that have been used in clinical studies 
fulfill all properties and development of better protocols in existing radiotracers 
and search in new tracers is still on-going. Furthermore, there is a lack of studies 
verifying hypoxia in hypoxic subvolumes seen on hypoxia PET imaging.
Prognostic value of EGFR and PTEN
The epidermal growth factor receptor (EGFR) is a transmembrane protein that is 
a receptor tyrosine kinase for extracellular ligands such as EGF. Ligand-binding 
to EGFR induces activation of the intrinsic kinase domain and stimulation of 
downstream signaling pathways such as the P13K/AKT pathway, regulating 
numerous cellular responses such as increased cell proliferation, decreased 
insensitivity to apoptosis, migration and differentiation13. Increased expression of 
EGFR is commonly observed in many human cancers including head and neck68-70. 
Furthermore, EGFR expression has been significantly correlated with poor local 
control after radio- or chemotherapy in different cancer types, including head 
and neck cancer71-74. Consequently, intensive research has focused on EGFR as 
potential target for cancer therapy. Although expression of EGFR is not a predictor 
for response to cetuximab, a monoclonal antibody targeting EGFR75, patients with 
HNSCC independent of EGFR status also significantly benefit from treatment with 
cetuximab10. Since 2006, the use of cetuximab is approved by the FDA and EMA in 
combination with radiotherapy for patients with locally advanced non-metastatic 
HNSCC in case chemoradiation is not feasible11. 
Another mechanism for PI3K/AKT pathway activation is the loss of PTEN 
(phosphatase and tensin homolog deleted on chromosome 10), a tumor suppressor 
gene which opposes PI3K/AKT activation11,76,77. PTEN is the second most affected 
tumor suppressor gene after p53 and mutations/deletions in PTEN are found in a 
variety of primary tumors including HNSCC78-82. In a cohort of patients with locally 
advanced HNSCC postoperatively treated with radiotherapy, overexpression of 
PTEN was associated with increased radioresistance83, in line with an alternative 
role of PTEN in DNA damage repair82,84.
DNA damage response markers as biomarkers for radiation response
During radiotherapy, DNA double strand breaks (DSBs) are introduced to cause 
cell death. DSBs activate a complex DNA damage response (DDR) pathway that 
controls cell cycle checkpoints, DNA repair and apoptosis85. Central in the DDR is the 
protein kinase ataxia telangiectasia mutated protein (ATM)86-91. DNA DSB induced 




by ionizing radiation leads to activation of ATM and subsequently phosphorylates 
a variety of substrates including the checkpoint kinase 2 (Chk2) which is known 
to prevent entry into mitosis. Both phosphorylated ATM and Chk2 are known to 
activate the tumor suppressor gene p53 with cell cycle arrest and apoptosis86-90.
In patients with cervical cancer treated with (chemo)radiation, high levels of 
phosphorylated ATM were linked to poor locoregional disease-free survival and 
inhibition of ATM sensitizes cell lines to radiation92. Although inhibition of ATM 
was also demonstrated to sensitize HNSCC cell lines to radiation93,94, only few 
studies using tumor tissues from patients with head and neck cancer showed no 
relation between ATM expression and response to chemo(radiation)95,96. 
Epigenetic changes as prognosticator in LSCC treated with radiotherapy
DNA methylation is one of the major forms of epigenetic regulation of gene 
expression. Among others, it plays an important role in tumorigenesis leading to 
the epigenetic modulation of the expression of tumor suppressor genes involved 
in cell cycle regulation, apoptosis, and DNA repair97-99. In cancer, DNA methylation 
becomes aberrant, causing global hypomethylation and local hypermethylation 
in tumor suppressor genes as compared to normal cells100. DNA methylation was 
found to be associated with clinical outcome in HNSCC in our research group101-103 
and others104,105. 
DNA methylation is regulated by the DNA methyltransferase (DNMT) enzymes 
such as DNMT1, DNMT3A and DNMT3B97. High expression of DNMT’s in a variety 
of tumors was associated with hypermethylation and oncogenic activation106. 
DNMT1 expression correlates well with aberrant DNA methylation in solid tumors, 
including esophageal carcinomas resulting in poor prognosis in patients107. DNMT1 
expression positively correlated with radiation sensitization and longer survival of 
esophageal squamous cell carcinoma patients108. Furthermore, positive staining 
for DNMT1 was significantly linked to lower rates of treatment response and 
shorter survival of patients with pharyngeal squamous cell carcinoma treated with 
surgery combined with adjuvant radiotherapy with/without chemotherapy, or 
definitive concurrent chemoradiotherapy109. DNMT inhibitors were demonstrated 
to sensitize HNSCC cell lines to irradiation110. Epigenetic therapies, such as with 
DNMT1 inhibitors used in clinical practice (like azacitidine, decitabine, zebularine)111 
leading to hypomethylation of DNA, might offer new opportunities for modulating 
the radiation resistance of tumors112.
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OUTLINE OF THIS THESIS




) LSCC radiotherapy is the preferred choice of treatment because 
of laryngeal preservation. Despite the relatively high treatment response rate after 
radiotherapy a considerable number of patients will develop a local recurrence, 
which consequently requires salvage surgery (i.e. total laryngectomy) with high 
morbidity and deterioration of quality of life. For individual patients, it would 
be useful to predict local tumor control after radiotherapy on the pre-treatment 
biopsy. In HNSCC many studies have been performed to identify prognostic tumor 
biomarkers. However, diversity in staining protocols and in the composition of 
study populations makes it difficult to compare the reported results and determine 
the clinical value of these biomarkers as prognostic factors for local control.
In the first part of this thesis (Chapter 2 and 3), the feasibility of a hypoxia 
PET tracer is investigated. In the second part of this thesis (Chapter 4, 5 and 6), 
tumor biomarkers associated with local control are investigated in a well-defined 
homogeneous cohort of early stage (T1-T2) glottic and supraglottic LSCC patients 
all treated with curatively intended radiotherapy. For this purpose, we used 
a bio-database covering 1286 patients diagnosed with LSCC at the department 
of Otorhinolaryngology/ Head & Neck Surgery in the University Medical Center 
Groningen (UMCG) between 1990 and 2008. Clinicopathological baseline 
and follow-up data were available from the archives of the departments of 
Otorhinolaryngology/ Head & Neck Surgery, Pathology and Radiation Oncology. 
Formalin-fixed and paraffin-embedded pre-treatment tissue biopsies with 
sufficient neoplastic cells were selected for immunohistochemical analysis.
Chapter 2 gives a comprehensive review on different animal and human 
18F-FAZA-PET studies and its potential use for individualized treatment in patients 
with hypoxic head and neck tumors. In Chapter 3, the accuracy of 18F-FAZA-PET/CT 
scan in detecting hypoxic regions within the tumor using exogenous (pimonidazole) 
and endogenous (HIF1α, CA-IX and GLUT-1) immunohistochemical markers is 
investigated. For this purpose 11 patients were selected (outside previous mentioned 
database) with an indication for total laryngectomy because of locally advanced or 
recurrent laryngeal carcinoma. The prognostic value of EGFR and PTEN expression 
on local control in 52 patients from our database with early-stage supraglottic 
LSCC treated with radiotherapy, is evaluated in Chapter 4. The prognostic value 
of the immunohistochemical expression of pATM, pChk2 and p53, all involved 
in the ATM-associated DNA damage response pathway, is investigated in our 




series of patients with early-stage LSCC treated with radiotherapy in Chapter 5. 
Because DNA methylation is regulated by DNMT1, in Chapter 6 we investigate the 
association between DNMT1 expression and local control in LSCC patients treated 
with radiotherapy. Chapter 7 provides a summary, general discussion and some 
future perspectives. Chapter 8 provides a Dutch summary of the results.
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